Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.43 |
| ▸ | ABL1 | P00519 | 5/20 | 0.42 |
| ▸ | BCR | P11274 | 5/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13435317 | 0.92 | PAK1 (0.44) | MAPK14ABL1BCRKDRKCNH2 | |
| SCHEMBL14098861 | 0.89 | MAPK14 (0.44) | MAPK14CYP2C9ABL1BCRKDR | |
| SCHEMBL4215057 | 0.88 | MAPK14 (0.43) | MAPK14CYP2C9ABL1BCRKDR | |
| SCHEMBL4230063 | 0.87 | ABL1 (0.48) | MAPK14CYP2C9ABL1BCRKDR | |
| SCHEMBL4225132 | 0.85 | MAP2K4 (0.47) | MAPK14CYP2C9ABL1BCRKDR | |
| SCHEMBL4220579 | 0.84 | MAPK1 (0.42) | MAPK14CYP2C9ABL1BCRKDR | |
| SCHEMBL3525330 | 0.84 | MAPK14 (0.51) | MAPK14ABL1BCRKDRKCNH2 | |
| SCHEMBL4219255 | 0.84 | MAP2K4 (0.49) | MAPK14CYP2C9HDAC6GSK3BMAPK1 | |
| SCHEMBL4228198 | 0.83 | MAP2K4 (0.45) | MAPK14CYP2C9ABL1BCRKCNH2 | |
| SCHEMBL4219380 | 0.83 | MAPK1 (0.52) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687532-B2 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of I.A. rheumatoid arthritis | GLAXOSMITHKLINE LLC (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687532-B2 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of I.A. rheumatoid arthritis | GLAXOSMITHKLINE LLC (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687532-B2 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of I.A. rheumatoid arthritis | GLAXOSMITHKLINE LLC (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2009-01-22 | — | — | US | disclosed |
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2009-01-22 | — | — | US | disclosed |
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2009-01-22 | — | — | US | disclosed |
| EP-1708996-B1 | FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1708996-B1 | FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20070142372-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthritis | GLAXOSMITHKLINE LLC | 2007-06-21 | — | — | US | disclosed |
| US-20070142372-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthritis | GLAXOSMITHKLINE LLC | 2007-06-21 | — | — | US | disclosed |
| US-20070142372-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthritis | GLAXOSMITHKLINE LLC | 2007-06-21 | — | — | US | disclosed |
| EP-1708996-A1 | FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005073189-A1 | FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | MAPK1, MAPKAPK2, MAPK7 | MAPK14 19/4885CYP2C9 3757/4885ABL1 170/4885 |
| US-20070142372-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthritis | CNKSR1, MAPK1, MAPK7 | MAPK14 10/4885CYP2C9 2849/4885ABL1 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.